Auranofin (34031-32-8) is a disease-modifying antirheumatic drug (DMARD) , It is a potent inhibitor of selenoenzyme thioredoxin reductase and IκB kinase (IKK) by modifying Cys-179. Auranofin is an efficient inducer of mitochondrial membrane permeability transition pore in the presence of calcium ions.
1) Columbo et al. (1990), Modulation of mediator release from human basophils and pulmonary mast cells and macrophages by auranofin; Biochem. Pharmacol., 39 285
2) Rigobello et al. (2002), Induction of mitochondrial permeability transition by auranofin, a gold(I)-phosphine derivative; Br.J. Pharmacol., 136 1162
3) Merck 14 878